Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 124 articles: HTML format

Single Articles

April 2024
1. OMOLEYE OJ, Esserman LJ, Olopade OI
   RE: Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density.
   J Natl Cancer Inst. 2024;116:627-628.
   PubMed    
   
   
   
2. VILLY MC, Le Ven A, Le Mentec M, Masliah-Planchon J, et al
   Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variants.
   J Natl Cancer Inst. 2024;116:580-587.
   PubMed     Abstract available
   
   
   
3. SANDOVAL RL, Bottosso M, Tianyu L, Polidorio N, et al
   TP53-associated early breast cancer: new observations from a large cohort.
   J Natl Cancer Inst. 2024 Apr 3:djae074. doi: 10.1093.
   PubMed     Abstract available
   
   
   March 2024
4. ZENG E, He W, Sjolander A, Bergqvist J, et al
   Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis.
   J Natl Cancer Inst. 2024 Mar 12:djae061. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. HUBBARD RA, Su YR, Bowles EJ, Ichikawa L, et al
   Predicting five-year interval second breast cancer risk in women with prior breast cancer.
   J Natl Cancer Inst. 2024 Mar 11:djae063. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. LEE CI, Elmore JG
   Beyond survival: a closer look at lead-time bias and disease-free intervals in mammography screening.
   J Natl Cancer Inst. 2024;116:343-344.
   PubMed    
   
   
   
7. KUMAR N, Ehsan S, Banerjee S, Fernandez Perez C, et al
   The unique risk factor profile of triple negative breast cancer: a comprehensive meta-analysis.
   J Natl Cancer Inst. 2024 Mar 5:djae056. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2024
8. LI JL, McClellan JC, Zhang H, Gao G, et al
   Multi-tissue transcriptome-wide association studies identified 235 genes for intrinsic subtypes of breast cancer.
   J Natl Cancer Inst. 2024 Feb 23:djae041. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. XIAO Q, Mao X, Ploner A, Grassmann F, et al
   Cancer risks among first-degree relatives of women with a genetic predisposition to breast cancer.
   J Natl Cancer Inst. 2024 Feb 14:djae030. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. KERLIKOWSKE K, Zhu W, Su YR, Sprague BL, et al
    Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density.
    J Natl Cancer Inst. 2024;116:249-257.
    PubMed     Abstract available
    
    
    January 2024
11. YANGUELA J, Jackson BE, Reeder-Hayes KE, Roberson ML, et al
    Simulating the population impact of interventions to reduce racial gaps in breast cancer treatment.
    J Natl Cancer Inst. 2024 Jan 27:djae019. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2023
12. O'SULLIVAN CC, Ruddy KJ
    Improving our treatment of breast cancer during pregnancy.
    J Natl Cancer Inst. 2023 Dec 29:djad259. doi: 10.1093.
    PubMed    
    
    
    
13. CESCON DW, Schmid P, Rugo HS, Im SA, et al
    Health-Related Quality of Life With Pembrolizumab+Chemotherapy Versus Placebo+Chemotherapy for Advanced Triple-Negative Breast Cancer: KEYNOTE-355.
    J Natl Cancer Inst. 2023 Dec 9:djad240. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. FERRIGNO GUAJARDO AS, Vaca-Cartagena BF, Mayer EL, Bousrih C, et al
    Taxanes for the treatment of breast cancer during pregnancy: an international cohort study.
    J Natl Cancer Inst. 2023 Dec 7:djad219. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2023
15. SALWEI ME, Ancker JS, Weinger MB
    The decision aid is the easy part: workflow challenges of shared decision making in cancer care.
    J Natl Cancer Inst. 2023;115:1271-1277.
    PubMed     Abstract available
    
    
    
16. DE MUNCK L, Eijkelboom AH, Otten JDM, Broeders MJM, et al
    Method of primary breast cancer detection and the disease-free interval, adjusting for lead time.
    J Natl Cancer Inst. 2023 Nov 3:djad230. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2023
17. METEKOUA C, Ruffieux Y, Olago V, Dhokotera T, et al
    Decreasing incidence of conjunctival squamous cell carcinoma in people with HIV in South Africa.
    J Natl Cancer Inst. 2023;115:1213-1219.
    PubMed     Abstract available
    
    
    September 2023
18. 
    Correction to: Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
    J Natl Cancer Inst. 2023 Sep 27:djad197. doi: 10.1093.
    PubMed    
    
    
    
19. WHITE AJ, Fisher JA, Sweeney MR, Freedman ND, et al
    Ambient fine particulate matter and breast cancer incidence in a large prospective US cohort.
    J Natl Cancer Inst. 2023 Sep 11:djad170. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. WOLFSON EA, Schonberg MA, Eliassen AH, Bertrand KA, et al
    Validating a Model for Predicting Breast Cancer and Non-Breast Cancer Death in Women Aged 55 and Older.
    J Natl Cancer Inst. 2023 Sep 7:djad188. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. DIECI MV, Conte PP, Bisagni PG, Bartolini S, et al
    Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
    J Natl Cancer Inst. 2023 Sep 7:djad179. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. BALAZARD F, Bertaut A, Bordet E, Mulard S, et al
    Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.
    J Natl Cancer Inst. 2023;115:1099-1108.
    PubMed     Abstract available
    
    
    
23. SHUMWAY DA, Corbin KS, Farah MH, Viola KE, et al
    Partial breast irradiation compared with whole breast irradiation: a systematic review and meta-analysis.
    J Natl Cancer Inst. 2023;115:1011-1019.
    PubMed     Abstract available
    
    
    August 2023
24. LEE MK, Robson ME
    Contralateral breast cancer risk with radiation therapy in BRCA mutation carriers: what do we tell patients?
    J Natl Cancer Inst. 2023 Aug 21:djad129. doi: 10.1093.
    PubMed    
    
    
    
25. WANG H, Ding XH, Liu CL, Xiao Y, et al
    Genomic alterations impacting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.
    J Natl Cancer Inst. 2023 Aug 7:djad154. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2023
26. KRESOVICH JK, O'Brien KM, Xu Z, Weinberg CR, et al
    Changes in methylation-based aging in women who do and do not develop breast cancer.
    J Natl Cancer Inst. 2023 Jul 19:djad117. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. KEEGAN G, Rizzo JR, Joseph KA
    Disparities in Breast Cancer Patients with Disabilities: Care Gaps, Accessibility, and Best Practices.
    J Natl Cancer Inst. 2023 Jul 8:djad130. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. ELZE L, van der Post RS, Vos JR, Mensenkamp AR, et al
    Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome.
    J Natl Cancer Inst. 2023;115:853-860.
    PubMed     Abstract available
    
    
    
29. CHOW R, Hasan S, Choi JI, Fox J, et al
    Effect of Treatment Interruptions on Overall Survival in Patients with Triple Negative Breast Cancer.
    J Natl Cancer Inst. 2023 Jul 3:djad127. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2023
30. SYMONDS LK, Davidson NE
    Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer.
    J Natl Cancer Inst. 2023 Jun 30:djad111. doi: 10.1093.
    PubMed    
    
    
    
31. VAN BARELE M, Akdeniz D, Heemskerk-Gerritsen BAM, Andrieu N, et al
    Contralateral breast cancer risk in irradiated breast cancer patients with a germline-BRCA1/2 pathogenic variant.
    J Natl Cancer Inst. 2023 Jun 27:djad116. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. LI S, Nguyen-Dumont T, Southey MC, Hopper JL, et al
    RE: Heterozygous BRCA1 and BRCA2 and mismatch repair gene pathogenic variants in children and adolescents with cancer.
    J Natl Cancer Inst. 2023;115:757-759.
    PubMed    
    
    
    
33. LUYENDIJK M, Visser O, Blommestein HM, de Hingh IHJT, et al
    Changes in survival in de novo metastatic cancer in an era of new medicines.
    J Natl Cancer Inst. 2023;115:628-635.
    PubMed     Abstract available
    
    
    May 2023
34. WANG Q, Zhang Y, Zeng E, Grassmann F, et al
    Risk of ER-specific breast cancer by family history of ER subtypes and other cancers.
    J Natl Cancer Inst. 2023 May 27:djad104. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. MAO X, He W, Eriksson M, Lindstrom LS, et al
    Prediction of breast cancer risk for sisters of women attending screening.
    J Natl Cancer Inst. 2023 May 27:djad101. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. ANTOINE A, Perol D, Robain M, Delaloge S, et al
    Target trial emulation to assess real-world efficacy in the ESME metastatic breast cancer cohort.
    J Natl Cancer Inst. 2023 May 23:djad092. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. VAN CAUWENBERGE J, Borremans K, Van Houdt M, Deblander A, et al
    RE: Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study.
    J Natl Cancer Inst. 2023 May 22:djad089. doi: 10.1093.
    PubMed    
    
    
    
38. MAMOUNAS EP, Bandos H, Rastogi P, Lembersky BC, et al
    Ten-year Update: NRG Oncology/NSABP B-42 Randomized Trial: Extended Letrozole Therapy in Early-stage Breast Cancer.
    J Natl Cancer Inst. 2023 May 15:djad078. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. KIM MH, Kim GM, Ahn JM, Ryu WJ, et al
    Copy number aberrations in ctDNA enables prognosis prediction and molecular characterization of breast cancer.
    J Natl Cancer Inst. 2023 May 11:djad080. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. LI R, Sant S, Brown E, Caramia F, et al
    Tucatinib promotes immune activation and synergises with PD-1/PD-L1 inhibition in HER2-positive breast cancer.
    J Natl Cancer Inst. 2023 May 11:djad072. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2023
41. MAYERHOFER C, Sedrak MS, Hopkins JO, Li T, et al
    Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy.
    J Natl Cancer Inst. 2023 Apr 12:djad065. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. BERTUCCI F, DE Nonneville A, Finetti P, Mamessier E, et al
    RE: [HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1].
    J Natl Cancer Inst. 2023 Apr 2:djad060. doi: 10.1093.
    PubMed    
    
    
    March 2023
43. WIESE D, Islami F, Henry KA
    Changes in geographic accessibility to mammography by state and rural-urban status, United States, 2006-2022.
    J Natl Cancer Inst. 2023;115:337-340.
    PubMed     Abstract available
    
    
    
44. 
    Correction to: RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study.
    J Natl Cancer Inst. 2023 Mar 6:djad041. doi: 10.1093.
    PubMed    
    
    
    February 2023
45. LOVETT SM, Sandler DP, O'Brien KM
    Hysterectomy, bilateral oophorectomy, and breast cancer risk in a racially diverse prospective cohort study.
    J Natl Cancer Inst. 2023 Feb 20:djad038. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. 
    Correction to: TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.
    J Natl Cancer Inst. 2023 Feb 16:djad023. doi: 10.1093.
    PubMed    
    
    
    
47. CHAVEZ-MACGREGOR M, Lei X, Malinowski C, Zhao H, et al
    Medicaid expansion, chemotherapy delays, and racial disparities among women with early-stage breast cancer.
    J Natl Cancer Inst. 2023 Feb 16:djad033. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. BIKOMEYE JC, Zhou Y, McGinley EL, Canales B, et al
    Historical Redlining and Breast Cancer Treatment and Survival among older Women in the US.
    J Natl Cancer Inst. 2023 Feb 16:djad034. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. MALTONI R, Puccetti M, Poli F, Martinelli G, et al
    Re: Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer.
    J Natl Cancer Inst. 2023 Feb 10:djad021. doi: 10.1093.
    PubMed    
    
    
    
50. JI J, Sun CL, Cohen HJ, Muss HB, et al
    Toxicity Risk Score and Clinical Decline After Adjuvant Chemotherapy in Older Breast Cancer Survivors.
    J Natl Cancer Inst. 2023 Feb 10:djad029. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. EVANS DG, Woodward ER
    RE: Heterozygous BRCA1/BRCA2 and mismatch repair gene pathogenic variants in children and adolescents with cancer.
    J Natl Cancer Inst. 2023;115:224-225.
    PubMed    
    
    
    January 2023
52. JONES RR, Fisher JA, Medgyesi DN, Buller ID, et al
    Ethylene oxide emissions and incident breast cancer and non-Hodgkin lymphoma in a U.S. cohort.
    J Natl Cancer Inst. 2023 Jan 12:djad004. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. JENSEN BW, Aarestrup J, Blond K, Jorgensen ME, et al
    Childhood body mass index trajectories, adult-onset type 2 diabetes, and obesity-related cancers.
    J Natl Cancer Inst. 2023;115:43-51.
    PubMed     Abstract available
    
    
    December 2022
54. LEONE JP, Freedman RA, Leone J, Tolaney SM, et al
    Survival in male breast cancer over the past three decades.
    J Natl Cancer Inst. 2022 Dec 30:djac241. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. BRASO-MARISTANY F, Griguolo G, Chic N, Pascual T, et al
    HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
    J Natl Cancer Inst. 2022 Dec 28:djac227. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. BADVE SS, Gokmen-Polar Y
    A predictor of response in HER2+ breast cancer-at last!
    J Natl Cancer Inst. 2022 Dec 28:djac228. doi: 10.1093.
    PubMed    
    
    
    
57. LANGE M, Arbogast SL, Hardy-Leger I, Rigal O, et al
    Cognitive change in breast cancer patients up to 2 years after diagnosis.
    J Natl Cancer Inst. 2022 Dec 26:djac240. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. DENG Z, Jones MR, Wang MC, Wolff AC, et al
    Racial and ethnic disparities in mortality among breast cancer survivors after a second malignancy.
    J Natl Cancer Inst. 2022 Dec 19:djac220. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. CHANG CJ, O'Brien KM, Keil AP, Gaston SA, et al
    Use of Straighteners and Other Hair Products and Incident Uterine Cancer.
    J Natl Cancer Inst. 2022;114:1636-1645.
    PubMed     Abstract available
    
    
    
60. CHAPMAN CH, Jagsi R, Griffith KA, Moran JM, et al
    Mediators of Racial Disparities in Heart Dose Among Whole Breast Radiotherapy Patients.
    J Natl Cancer Inst. 2022;114:1646-1655.
    PubMed     Abstract available
    
    
    November 2022
61. CHLEBOWSKI RT, Aragaki AK, Pan K
    RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study.
    J Natl Cancer Inst. 2022 Nov 21:djac213. doi: 10.1093.
    PubMed    
    
    
    
62. PEDERSON HJ, Faubion SS, Pruthi S, Goldfarb S, et al
    RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study.
    J Natl Cancer Inst. 2022 Nov 21:djac211. doi: 10.1093.
    PubMed    
    
    
    
63. DJERROUDI L, Cabel L, Bidard FC, Vincent-Salomon A, et al
    Invasive Lobular Carcinoma of the Breast: Toward Tailoring Therapy?
    J Natl Cancer Inst. 2022;114:1434-1436.
    PubMed    
    
    
    
64. KRATZ CP, Smirnov D, Autry R, Jager N, et al
    Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer.
    J Natl Cancer Inst. 2022;114:1523-1532.
    PubMed     Abstract available
    
    
    
65. KRAUT R
    RE: Informing Women about Overdetection in Breast Cancer Screening: Two-Year Outcomes from a Randomized Trial.
    J Natl Cancer Inst. 2022 Nov 4. pii: 6798630. doi: 10.1093.
    PubMed    
    
    
    October 2022
66. LIM BWX, Li N, Mahale S, Mcinerny S, et al
    Somatic Inactivation of Breast Cancer Predisposition Genes in Tumours Associated with Pathogenic Germline Variants.
    J Natl Cancer Inst. 2022 Oct 31. pii: 6782963. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. OESTERREICH S, Nasrazadani A, Zou J, Carleton N, et al
    Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer.
    J Natl Cancer Inst. 2022 Oct 14. pii: 6758318. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. LEE CI, Elmore JG
    Cancer Risk Prediction Paradigm Shift: Using Artificial Intelligence to Improve Performance and Health Equity.
    J Natl Cancer Inst. 2022;114:1317-1319.
    PubMed    
    
    
    
69. CATHCART-RAKE EJ, Ruddy KJ
    Vaginal Estrogen Therapy for the Genitourinary Symptoms of Menopause: Caution or Reassurance?
    J Natl Cancer Inst. 2022;114:1315-1316.
    PubMed    
    
    
    
70. SUNG H, Koka H, Marino N, Pfeiffer RM, et al
    Association of Genetic Ancestry With Terminal Duct Lobular Unit Involution Among Healthy Women.
    J Natl Cancer Inst. 2022;114:1420-1424.
    PubMed     Abstract available
    
    
    September 2022
71. COGAN JC, Raghunathan RR, Beauchemin MP, Accordino MK, et al
    New and Persistent Sedative-Hypnotic Use after Adjuvant Chemotherapy for Breast Cancer.
    J Natl Cancer Inst. 2022 Sep 20. pii: 6706799. doi: 10.1093.
    PubMed     Abstract available
    
    
    
72. BOWER JE, Partridge AH, Wolff AC, Cole SW, et al
    Improving biobehavioral health in younger breast cancer survivors: Pathways to Wellness trial secondary outcomes.
    J Natl Cancer Inst. 2022 Sep 20. pii: 6706813. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. RICHMAN I, Tessier-Sherman B, Galusha D, Oladele CR, et al
    Breast Cancer Screening During the COVID-19 Pandemic: Moving from Disparities to Health Equity.
    J Natl Cancer Inst. 2022 Sep 7. pii: 6693627. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2022
74. LAMBERTINI M, Fielding S, Loibl S, Janni W, et al
    Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.
    J Natl Cancer Inst. 2022;114:1117-1126.
    PubMed     Abstract available
    
    
    
75. PUNGLIA RS, Hassett MJ
    Variation in Cardiac Dose Explains a "Fraction" of the Disparities among Breast Cancer Patients.
    J Natl Cancer Inst. 2022 Aug 2. pii: 6653305. doi: 10.1093.
    PubMed    
    
    
    
76. SCHUMACHER JR, Neuman HB, Yu M, Vanness DJ, et al
    Surveillance imaging vs symptomatic recurrence detection and survival in stage II-III breast cancer (AFT-01).
    J Natl Cancer Inst. 2022 Aug 1. pii: 6652887. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2022
77. LEHMAN CD, Mercaldo S, Lamb LR, King TA, et al
    Deep Learning vs Traditional Breast Cancer Risk Models to Support Risk-Based Mammography Screening.
    J Natl Cancer Inst. 2022 Jul 25. pii: 6649701. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. COLD S, Cold F, Jensen MB, Cronin-Fenton D, et al
    Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study.
    J Natl Cancer Inst. 2022 Jul 20. pii: 6645744. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. LIGORIO F, Di Cosimo S, Verderio P, Ciniselli CM, et al
    Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab.
    J Natl Cancer Inst. 2022 Jul 5. pii: 6631230. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2022
80. ROBERTI S, van Leeuwen FE, Ronckers CM, Krul IM, et al
    Radiotherapy-related dose and irradiated volume effects on breast cancer risk among Hodgkin lymphoma survivors.
    J Natl Cancer Inst. 2022 Jun 30. pii: 6623416. doi: 10.1093.
    PubMed     Abstract available
    
    
    
81. JUNG AY, Ahearn TU, Behrens S, Middha P, et al
    Distinct reproductive risk profiles for intrinsic-like breast cancer subtypes: pooled analysis of population-based studies.
    J Natl Cancer Inst. 2022 Jun 20. pii: 6611725. doi: 10.1093.
    PubMed     Abstract available
    
    
    
82. SCHEDIN P, Palmer JR
    Can breast cancer prevention strategies be tailored to biologic subtype and unique reproductive windows?
    J Natl Cancer Inst. 2022 Jun 20. pii: 6611724. doi: 10.1093.
    PubMed    
    
    
    
83. MOSS JL, Pinto CN, Srinivasan S, Cronin KA, et al
    Enduring Cancer Disparities by Persistent Poverty, Rurality, and Race: 1990-1992 to 2014-2018.
    J Natl Cancer Inst. 2022;114:829-836.
    PubMed     Abstract available
    
    
    
84. KEATING NL, Brooks GA, Landrum MB, Liu PH, et al
    The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.
    J Natl Cancer Inst. 2022;114:871-877.
    PubMed     Abstract available
    
    
    April 2022
85. SCHRIJVER LH, Mooij TM, Pijpe A, Sonke GS, et al
    Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
    J Natl Cancer Inst. 2022;114:540-552.
    PubMed     Abstract available
    
    
    
86. KRIEGER N
    RE: Decreasing Incidence of Estrogen Receptor-Negative Breast Cancer in the United States: Trends by Race and Region.
    J Natl Cancer Inst. 2022 Apr 4. pii: 6563193. doi: 10.1093.
    PubMed    
    
    
    
87. LOHMANN AE, Ennis M, Parulekar WR, Chen BE, et al
    The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor Positive Breast Cancer.
    J Natl Cancer Inst. 2022 Apr 4. pii: 6563195. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2022
88. QIN X, Huckfeldt P, Abraham J, Yee D, et al
    Hormonal Therapy Drug Switching, Out-of-Pocket Costs, and Adherence among Older Women with Breast Cancer.
    J Natl Cancer Inst. 2022 Mar 25. pii: 6554201. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. FANG Z, Song M, Lee DH, Giovannucci EL, et al
    The Role of Mendelian Randomization Studies in Deciphering the Effect of Obesity on Cancer.
    J Natl Cancer Inst. 2022;114:361-371.
    PubMed     Abstract available
    
    
    February 2022
90. DE NONNEVILLE A, Finetti P, Mamessier E, Bertucci F, et al
    RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.
    J Natl Cancer Inst. 2022 Feb 11. pii: 6527095. doi: 10.1093.
    PubMed    
    
    
    
91. BELCHER EK, Culakova E, Gilmore NJ, Hardy SJ, et al
    Inflammation, Attention, and Processing Speed in Patients with Breast Cancer before and after Chemotherapy.
    J Natl Cancer Inst. 2022 Feb 4. pii: 6522123. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2022
92. MOSKOWITZ CS
    Towards Using Breast Cancer Risk Prediction Models for Guiding Screening Decisions.
    J Natl Cancer Inst. 2022 Jan 13. pii: 6506526. doi: 10.1093.
    PubMed    
    
    
    
93. KERLIKOWSKE K, Chen S, Golmakani MK, Sprague BL, et al
    Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population.
    J Natl Cancer Inst. 2022 Jan 13. pii: 6506541. doi: 10.1093.
    PubMed     Abstract available
    
    
    
94. DACKUS GMHE, Jozwiak K, Hauptmann M, Linn SC, et al
    Response to Klar and Adams.
    J Natl Cancer Inst. 2022;114:167-168.
    PubMed    
    
    
    December 2021
95. SCHLEE VILLODRE E, Hu X, Eckhardt BL, Larson R, et al
    NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.
    J Natl Cancer Inst. 2021 Dec 10. pii: 6459176. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2021
96. ISLAMI F, Ward EM, Sung H, Cronin KA, et al
    Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics.
    J Natl Cancer Inst. 2021;113:1648-1669.
    PubMed     Abstract available
    
    
    
97. RUGO HS, Loi S, Adams S, Schmid P, et al
    PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2021;113:1733-1743.
    PubMed     Abstract available
    
    
    
98. GAVRIELATOU N, Shafi S, Gaule P, Rimm DL, et al
    PD-L1 Expression Scoring: Noninterchangeable, Noninterpretable, Neither, or Both.
    J Natl Cancer Inst. 2021;113:1613-1614.
    PubMed    
    
    
    
99. CUI W, Francis PA, Loi S, Hickey M, et al
    Assessment of Ovarian Function in Phase III (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
    J Natl Cancer Inst. 2021;113:1770-1778.
    PubMed     Abstract available
    
    
    
100. KANTOR O, King TA, Shak S, Russell CA, et al
     Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer.
     J Natl Cancer Inst. 2021;113:1744-1750.
     PubMed     Abstract available
     
     
     
101. BORGES VF
     The Expanded Role of Ovarian Suppression for Young Women's Breast Cancer: An Era of Patient-Tailored Decision Making.
     J Natl Cancer Inst. 2021 Nov 25. pii: 6440063. doi: 10.1093.
     PubMed    
     
     
     
102. LAMBERTINI M, Boni L, Michelotti A, Magnolfi E, et al
     Long-Term Outcomes with Pharmacological Ovarian Suppression during Chemotherapy in Premenopausal Early Breast Cancer Patients.
     J Natl Cancer Inst. 2021 Nov 25. pii: 6440062. doi: 10.1093.
     PubMed     Abstract available
     
     
     
103. NEGOITA S, Ramirez-Pena E
     Prevention of Late Recurrence: An Increasingly Important Target for Breast Cancer Research and Control.
     J Natl Cancer Inst. 2021 Nov 8. pii: 6423213. doi: 10.1093.
     PubMed    
     
     
     
104. PEDERSEN RN, Esen BO, Mellemkjaer L, Christiansen P, et al
     The Incidence of Breast Cancer Recurrence 10-32 Years after Primary Diagnosis.
     J Natl Cancer Inst. 2021 Nov 8. pii: 6423212. doi: 10.1093.
     PubMed     Abstract available
     
     
     
105. GEUZINGE HA, Bakker MF, Heijnsdijk EAM, van Ravesteyn NT, et al
     Cost-Effectiveness of Magnetic Resonance Imaging Screening for Women With Extremely Dense Breast Tissue.
     J Natl Cancer Inst. 2021;113:1476-1483.
     PubMed     Abstract available
     
     
     
106. KUHL CK, Baltzer P
     You Get What You Pay For: Breast MRI Screening of Women With Dense Breasts Is Cost-effective.
     J Natl Cancer Inst. 2021;113:1439-1441.
     PubMed    
     
     
     
107. NIELSEN TO, Leung SCY, McShane LM, Dowsett M, et al
     Response to Zhang and Yang.
     J Natl Cancer Inst. 2021;113:1597-1598.
     PubMed    
     
     
     October 2021
108. MANDELBLATT JS, Zhou X, Small BJ, Ahn J, et al
     Response to Dekker, Stege, and Versteeg.
     J Natl Cancer Inst. 2021;113:1436-1437.
     PubMed    
     
     
     
109. NICKEL B, Copp T, Brennan M, Farber R, et al
     The Impact of Breast Density Information or Notification on Women's Cognitive, Psychological, and Behavioral Outcomes: A Systematic Review.
     J Natl Cancer Inst. 2021;113:1299-1328.
     PubMed     Abstract available
     
     
     September 2021
110. SPRAGUE BL, Lowry KP, Miglioretti DL, Alsheik N, et al
     Changes in Mammography Use by Women's Characteristics During the First 5 Months of the COVID-19 Pandemic.
     J Natl Cancer Inst. 2021;113:1161-1167.
     PubMed     Abstract available
     
     
     
111. DE JONGE MM, de Kroon CD, Jenner DJ, Oosting J, et al
     Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
     J Natl Cancer Inst. 2021;113:1203-1211.
     PubMed     Abstract available
     
     
     
112. JATOI I, Pinsky PF
     Breast Cancer Screening Trials: Endpoints and Overdiagnosis.
     J Natl Cancer Inst. 2021;113:1131-1135.
     PubMed     Abstract available
     
     
     August 2021
113. HERSHMAN DL, Neugut AI, Moseley A, Arnold KB, et al
     Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors.
     J Natl Cancer Inst. 2021;113:989-996.
     PubMed     Abstract available
     
     
     
114. YAO S, Cheng TD, Elkhanany A, Yan L, et al
     Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion.
     J Natl Cancer Inst. 2021;113:1036-1043.
     PubMed     Abstract available
     
     
     
115. RUDDY KJ, Schaid DJ, Batzler A, Cecchini RS, et al
     Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea.
     J Natl Cancer Inst. 2021;113:1105-1108.
     PubMed     Abstract available
     
     
     July 2021
116. BARNES DR, Silvestri V, Leslie G, McGuffog L, et al
     Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
     J Natl Cancer Inst. 2021 Jul 28. pii: 6329642. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2021
117. WANG J, Peng C, Guranich C, Heng YJ, et al
     Early-Life Body Adiposity and the Breast Tumor Transcriptome.
     J Natl Cancer Inst. 2021;113:778-784.
     PubMed     Abstract available
     
     
     May 2021
118. PUNGLIA RS, Partridge AH
     Optimizing Decision Making for Ductal Carcinoma in Situ: Facts Over Fear.
     J Natl Cancer Inst. 2021;113:511-512.
     PubMed    
     
     
     April 2021
119. VAN DEN BROEK JJ, Schechter CB, van Ravesteyn NT, Janssens ACJW, et al
     Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.
     J Natl Cancer Inst. 2021;113:434-442.
     PubMed     Abstract available
     
     
     
120. MAGUIRE S, Perraki E, Tomczyk K, Jones ME, et al
     Common Susceptibility Loci for Male Breast Cancer.
     J Natl Cancer Inst. 2021;113:453-461.
     PubMed     Abstract available
     
     
     
121. MAGBANUA MJM, Hendrix LH, Hyslop T, Barry WT, et al
     Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.
     J Natl Cancer Inst. 2021;113:443-452.
     PubMed     Abstract available
     
     
     
122. FRANZOI MA, Eiger D, Ameye L, Ponde N, et al
     Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
     J Natl Cancer Inst. 2021;113:462-470.
     PubMed     Abstract available
     
     
     March 2021
123. O'LEARY B, Cutts RJ, Huang X, Hrebien S, et al
     Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
     J Natl Cancer Inst. 2021;113:309-317.
     PubMed     Abstract available
     
     
     
124. KAPOOR PM, Mavaddat N, Choudhury PP, Wilcox AN, et al
     Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk.
     J Natl Cancer Inst. 2021;113:329-337.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.